Sirt6 upregulation was significantly associated with older age, higher IPI score, and later Ann Arbor stage in DLBCL patients, indicating its potential of being a prognostic factor to determine which patients may possess more aggressive diseases. The gene discussed is SIRT6; the disease is diffuse large B-cell lymphoma.